Manganese and its role in Parkinson's disease: From transport to neuropathology

Michael Aschner, Keith M. Erikson, Elena Herrero Hernández, Ronald Tjalkens

Research output: Contribution to journalArticle

171 Citations (Scopus)

Abstract

The purpose of this review is to highlight recent advances in the neuropathology associated with Mn exposures. We commence with a discussion on occupational manganism and clinical aspects of the disorder. This is followed by novel considerations on Mn transport (see also chapter by Yokel, this volume), advancing new hypotheses on the involvement of several transporters in Mn entry into the brain. This is followed by a brief description of the effects of Mn on neurotransmitter systems that are putative modulators of dopamine (DA) biology (the primary target of Mn neurotoxicity), as well as its effects on mitochondrial dysfunction and disruption of cellular energy metabolism. Next, we discuss inflammatory activation of glia in neuronal injury and how disruption of synaptic transmission and glial-neuronal communication may serve as underlying mechanisms of Mn-induced neurodegeneration commensurate with the cross-talk between glia and neurons. We conclude with a discussion on therapeutic aspects of Mn exposure. Emphasis is directed at treatment modalities and the utility of chelators in attenuating the neurodegenerative sequelae of exposure to Mn. For additional reading on several topics inherent to this review as well as others, the reader may wish to consult Aschner and Dorman (Toxicological Review 25:147-154, 2007) and Bowman et al. (Metals and neurodegeneration, 2009).

Original languageEnglish (US)
Pages (from-to)252-266
Number of pages15
JournalNeuroMolecular Medicine
Volume11
Issue number4
DOIs
StatePublished - Dec 2009
Externally publishedYes

Fingerprint

Manganese
Neuroglia
Parkinson Disease
Chelating Agents
Synaptic Transmission
Toxicology
Energy Metabolism
Neurotransmitter Agents
Reading
Dopamine
Metals
Neurons
Wounds and Injuries
Brain
Neuropathology
Therapeutics

Keywords

  • GABA
  • Glia
  • Glutamate
  • Manganese
  • MRI
  • Neuroinflammation
  • Parkinson's

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Molecular Medicine
  • Neurology

Cite this

Manganese and its role in Parkinson's disease : From transport to neuropathology. / Aschner, Michael; Erikson, Keith M.; Hernández, Elena Herrero; Tjalkens, Ronald.

In: NeuroMolecular Medicine, Vol. 11, No. 4, 12.2009, p. 252-266.

Research output: Contribution to journalArticle

Aschner, Michael ; Erikson, Keith M. ; Hernández, Elena Herrero ; Tjalkens, Ronald. / Manganese and its role in Parkinson's disease : From transport to neuropathology. In: NeuroMolecular Medicine. 2009 ; Vol. 11, No. 4. pp. 252-266.
@article{acf253cae1754d7a83c8e943e0fb36be,
title = "Manganese and its role in Parkinson's disease: From transport to neuropathology",
abstract = "The purpose of this review is to highlight recent advances in the neuropathology associated with Mn exposures. We commence with a discussion on occupational manganism and clinical aspects of the disorder. This is followed by novel considerations on Mn transport (see also chapter by Yokel, this volume), advancing new hypotheses on the involvement of several transporters in Mn entry into the brain. This is followed by a brief description of the effects of Mn on neurotransmitter systems that are putative modulators of dopamine (DA) biology (the primary target of Mn neurotoxicity), as well as its effects on mitochondrial dysfunction and disruption of cellular energy metabolism. Next, we discuss inflammatory activation of glia in neuronal injury and how disruption of synaptic transmission and glial-neuronal communication may serve as underlying mechanisms of Mn-induced neurodegeneration commensurate with the cross-talk between glia and neurons. We conclude with a discussion on therapeutic aspects of Mn exposure. Emphasis is directed at treatment modalities and the utility of chelators in attenuating the neurodegenerative sequelae of exposure to Mn. For additional reading on several topics inherent to this review as well as others, the reader may wish to consult Aschner and Dorman (Toxicological Review 25:147-154, 2007) and Bowman et al. (Metals and neurodegeneration, 2009).",
keywords = "GABA, Glia, Glutamate, Manganese, MRI, Neuroinflammation, Parkinson's",
author = "Michael Aschner and Erikson, {Keith M.} and Hern{\'a}ndez, {Elena Herrero} and Ronald Tjalkens",
year = "2009",
month = "12",
doi = "10.1007/s12017-009-8083-0",
language = "English (US)",
volume = "11",
pages = "252--266",
journal = "NeuroMolecular Medicine",
issn = "1535-1084",
publisher = "Humana Press",
number = "4",

}

TY - JOUR

T1 - Manganese and its role in Parkinson's disease

T2 - From transport to neuropathology

AU - Aschner, Michael

AU - Erikson, Keith M.

AU - Hernández, Elena Herrero

AU - Tjalkens, Ronald

PY - 2009/12

Y1 - 2009/12

N2 - The purpose of this review is to highlight recent advances in the neuropathology associated with Mn exposures. We commence with a discussion on occupational manganism and clinical aspects of the disorder. This is followed by novel considerations on Mn transport (see also chapter by Yokel, this volume), advancing new hypotheses on the involvement of several transporters in Mn entry into the brain. This is followed by a brief description of the effects of Mn on neurotransmitter systems that are putative modulators of dopamine (DA) biology (the primary target of Mn neurotoxicity), as well as its effects on mitochondrial dysfunction and disruption of cellular energy metabolism. Next, we discuss inflammatory activation of glia in neuronal injury and how disruption of synaptic transmission and glial-neuronal communication may serve as underlying mechanisms of Mn-induced neurodegeneration commensurate with the cross-talk between glia and neurons. We conclude with a discussion on therapeutic aspects of Mn exposure. Emphasis is directed at treatment modalities and the utility of chelators in attenuating the neurodegenerative sequelae of exposure to Mn. For additional reading on several topics inherent to this review as well as others, the reader may wish to consult Aschner and Dorman (Toxicological Review 25:147-154, 2007) and Bowman et al. (Metals and neurodegeneration, 2009).

AB - The purpose of this review is to highlight recent advances in the neuropathology associated with Mn exposures. We commence with a discussion on occupational manganism and clinical aspects of the disorder. This is followed by novel considerations on Mn transport (see also chapter by Yokel, this volume), advancing new hypotheses on the involvement of several transporters in Mn entry into the brain. This is followed by a brief description of the effects of Mn on neurotransmitter systems that are putative modulators of dopamine (DA) biology (the primary target of Mn neurotoxicity), as well as its effects on mitochondrial dysfunction and disruption of cellular energy metabolism. Next, we discuss inflammatory activation of glia in neuronal injury and how disruption of synaptic transmission and glial-neuronal communication may serve as underlying mechanisms of Mn-induced neurodegeneration commensurate with the cross-talk between glia and neurons. We conclude with a discussion on therapeutic aspects of Mn exposure. Emphasis is directed at treatment modalities and the utility of chelators in attenuating the neurodegenerative sequelae of exposure to Mn. For additional reading on several topics inherent to this review as well as others, the reader may wish to consult Aschner and Dorman (Toxicological Review 25:147-154, 2007) and Bowman et al. (Metals and neurodegeneration, 2009).

KW - GABA

KW - Glia

KW - Glutamate

KW - Manganese

KW - MRI

KW - Neuroinflammation

KW - Parkinson's

UR - http://www.scopus.com/inward/record.url?scp=72949123199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72949123199&partnerID=8YFLogxK

U2 - 10.1007/s12017-009-8083-0

DO - 10.1007/s12017-009-8083-0

M3 - Article

C2 - 19657747

AN - SCOPUS:72949123199

VL - 11

SP - 252

EP - 266

JO - NeuroMolecular Medicine

JF - NeuroMolecular Medicine

SN - 1535-1084

IS - 4

ER -